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Abstract
Behc¸et’s disease (BD) is a multifactorial disorder associated with the HLA region. Recently, the ERAP1 gene has been
proposed as a susceptibility locus with a recessive model and with epistatic interaction with HLA-B51. ERAP1 trims peptides
in the endoplasmic reticulum to optimize their length for MHC-I binding. Polymorphisms in this gene have been related
with the susceptibility to other immune-mediated diseases associated to HLA class I. Our aim was, the replication in the
Spanish population of the association described in the Turkish population between ERAP1 (rs17482078) and BD.
Additionally, in order to improve the understanding of this association we analyzed four additional SNPs (rs27044,
rs10050860, rs30187 and rs2287987) associated with other diseases related to HLA class I and the haplotype blocks in this
gene region. According to our results, frequencies of the homozygous genotypes for the minor alleles of all the SNPs were
increased among patients and the OR values were higher in the subgroup of patients with the HLA-B risk factors, although
differences were not statistically significant. Moreover, the presence of the same mutation in both chromosomes increased
the OR values from 4.51 to 10.72 in individuals carrying the HLA-B risk factors. Therefore, although they were not statistically
significant, our data were consistent with an association between ERAP1 and BD as well as with an epistatic interaction
between ERAP1 and HLA-B in the Spanish population.
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Introduction
Behc¸et disease (BD) is a multifactorial disorder with evidence of
genetic contribution based on familial aggregation, predominance
in patients with Mediterranean or Asian ancestry and association
with HLA-B51 in several ethnic groups [1–4]. Contribution of the
HLA region has been estimated to represent approximately 20%
of the genetic component of this disease [5]. In addition to the
HLA class I region, in which different peaks of association have
been detected, a relationship of the disease with IL23R and IL10
has been described using a large scale SNP genotyping strategy
(genome wide association studies, GWAS) in different Caucasian
and Asian populations [6–11].Very recently, the ERAP1 gene has
been proposed as a new susceptibility locus for BD in a Turkish
patient cohort [12].
The ERAP1 gene is located on chromosome 5q15 and it
encodes an amino-peptidase with an ubiquitous tissue distribution.
This enzyme is responsible for peptides N-terminal trimming in
the endoplasmic reticulum which is a critical step of the processing
of the peptides to optimize their length for MHC-I binding
[13,14]. Moreover, ERAP1 has been involved in the cleaving of
several proinflammatory cytokine receptors from the cell mem-
brane including shedding of tumor necrosis factor receptor
(TNFR1), IL-1 receptor-II (IL-RII) and IL-6 receptor a (IL-6 a)
[15–17] although this function remains to be confirmed.
Therefore, from a functional perspective, ERAP1 represents an
excellent biological candidate for association with BD. In fact, this
gene has been related with the susceptibility to other immune-
mediated diseases associated to HLA class I such as ankylosing
spondylitis (AS) and psoriasis [18–21] which have also been
associated with IL-23R and IL10 suggesting the existence of
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shared pathogenesis pathways [9–11,18,22,23]. In their study,
Kirino et al [12], described a recessive model of association with
BD in a Turkish population and they found an epistatic interaction
between HLA-B51 and ERAP1 which could not be replicated in a
Japanese cohort [12]. The objective of the present study was to
asses the association of ERAP1 with BD in the Spanish
population.
Methods
A total of 362 BD patients (148 males and 214 females) with a
mean age at onset 6 SD of 35.1611.2 fulfilled the 1990
International Study Group classification criteria for Behc¸et’s
disease [24] and 460 bone marrow and blood donors as normal
healthy controls (50% males) were included in the study. All the
subjects were Spanish European recruited from different Spanish
hospitals. The study was approved by all local ethical committees
of the corresponding hospitals A Coruna (CHU A Corun˜a),
Almerı´a (H. Torreca´rdenas), Barcelona (H. Clinic, Vall d’Hebron
and Mu´tua Terrassa), Granada (H. Clı´nico San Cecilio), Madrid
(H. de la Princesa), Ma´laga (H. Carlos Haya), Pamplona (H.
Virgen del Camino), Santander; (H Marques de Valdecilla) and
Sevilla (Virgen del Rocı´o and Valme). All the study participants
gave written informed consent according to the declaration of
Helsinki. Clinical features of the patient group were: 100% had
oral ulcers, 75% genital ulcers, 50% uveitis, 50% arthritis, and
25% vascular, 18% neurological and 19% gastrointestinal
involvement. The distribution of the frequencies of the different
markers in the cohorts from different hospitals was not
significantly different.
Peripheral blood was obtained from the healthy controls
whereas peripheral blood or saliva was the starting material
obtained from patients. Genomic DNA was extracted using
QIAmp DNA Mini Kit (Qiagen, Barcelona, Spain) according to
the manufacturer’s recommendations and stored at 220uC. The
purity of DNA was determined using a Nanodrop spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE 19810
U.S.A.). Only DNA samples having a 260/280 ratio between
1.7 and 2.0 and a final concentration of 10–20 ng/ml were
considered appropriate. Ten DNA samples from saliva were
eliminated because they did not meet these quality criteria.
Five non-synonymous single nucleotide polymorphisms (SNPs)
associated with AS rs27044 (Gln730Glu), rs17482078
(Arg725Gln), rs10050860 (Asp575Asn), rs30187 (Arg528Lys) and
rs2287987 (Val349Met) were included in this study. Genotyping of
these SNPs was performed using TaqMan SNP Genotyping
Assays (Applied Byosistems, Barcelona, Spain) in a LightCycler
480 (Roche, Barcelona, Spain). Patients and controls had been
previously genotyped in HLA-A and HLA-B using PCR-SSOP
Luminex method with LABType SSO (One Lambda Inc., Canoga
Park, CA), following the manufacturer’s instructions. According to
our previous results HLA-B*51 and HLA-B*57 were considered as
HLA-B risk factors in our population [25].
The a priori statistical power was calculated using the minor
allele frequencies (MAF) described in the European population for
the five SNPs included in this study (http://www.broadinstitute.
org/mammals/haploreg/haploreg.php), taking into consideration
a recessive association model of the minor alleles and the Odd
Ratio (OR) value described by Kirino et al for the rs17482078 in
their cohort (cases with and without uveitis and discovery and
replication data combined, OR = 3.08) [12] but using our sample
size (362 patients and 460 controls).
The different association models: genotypic, allelic, dominant
and recessive were tested using the x2 test and p values#0.05 were
considered statistically significant. The ORs and 95% confidence
intervals (95% CI) were calculated according to Wolf’s method
using StatCalc program (EPI Info 2002, Centers for Disease
Control and Prevention, Atlanta, GA, USA). The linkage
disequilibrium solid spine approach was used to define haplotype
blocks in the CEU and Spanish populations using the Haploview
program (available at the website http://www.broad.mit.edu/
mpg/haploview/download.php). The SNP haplotypes frequency
estimation in the CEU and Spanish populations was performed
using the Haploview sotfware. Conditional logistic regression
models were constructed by categorizing all the individuals
according to the presence/absence of the HLA-B risk factors
Table 1. Distribution of the five SNPs studied in ERAP1 according to a recessive model of the minor allele.
SNP MA TEST Patients Controls p OR
rs27044 G GG/CC+CG
Whole group 46/316 51/409 0.5 1.2
HLA-B Risk factor group 24/154 7/77 0.2 1.7
rs17482078 T TT/CC+CT
Whole group 17/344 12/446 0.1 1.8
HLA-B Risk factor group 6/172 1/83 0.3 2.8
rs10050860 T TT/CC+CT
Whole group 17/344 12/446 0.1 1.8
HLA-B Risk factor group 6/172 1/83 0.3 2.8
rs30187 T TT/CC+CT
Whole group 70/292 73/386 0.2 1.3
HLA-B Risk factor group 39/137 13/71 0.2 1.5
rs2287987 C CC/TT+CT
Whole group 17/344 12/446 0.1 1.8
HLA-B Risk factor group 6/172 1/83 0.3 2.8
Individuals with the HLA-B risk factors are subjects bearing HLA-B*51 and/or B*57.
doi:10.1371/journal.pone.0102100.t001
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(according to a dominant model), the ERAP1 haplotypes
(according to a recessive model) and the ERAP1 status (yes/no,
see results) analyzed with Epi Info 2002.
Results
The genotyping success ratio was greater than 95% and the
study population was found to be in the Hardy–Weinberg
equilibrium for all the polymorphisms analyzed (p.0.05). Table
S1 in File S1 displays genotype results of the SNPs included in the
study and statistical data of the different association models.
According to data displayed in Table S2 in File S1, the frequency
of the homozygous genotype of the minor allele of the rs17482078
in the healthy Spanish population is 2.6. Taking into account the
OR described by Kirino et al in their study (3.08) our a priori
statistical power for this SNP was 94.5.
The observed MAFs in the Spanish population were not
significantly different to those described in the European
population with the exception of the rs30187 which had a
significantly higher frequency of the minor allele (T) in our cohort
than in the European population included in the 1000 Genome
Phase I data project (0.41 vs. 0.34, p = 0.002) but similar to that
described in the other Spanish cohort [26]. According to our
results and in agreement with a recessive model, frequencies of the
homozygous genotypes for the minor alleles of all the SNPs were
increased among patients and the ORs ranging from 1.2 to 1.8
although differences were not statistically significant. The original
study also reported an epistatic interaction between ERAP1 and
HLA-B. Consistent with the original paper, the OR values for the
recessive models of the minor alleles of the five SNPs included in
the present study were higher in the subgroup of patients with the
HLA-B risk factors, although the differences were not statistically
significant (Table 1)
As it was previously described, linkage disequilibrium (LD)
among these 5 SNPs was found in the Spanish population. Table 2
shows the four haplotypes (named from H1 to H4) with
frequencies greater than 0.05 which were found in our patient
and control cohorts. The rs27044G, a risk factor for AS, tags the
haplotype H2, whereas the rs17482078T, which has been
described to be a risk factor in BD, and also the rs100504860T
and rs2287987C tag the haplotype H3. The three haplotypes
containing mutations: H2, H3 and H4 were slightly more common
among BD patients although the allelic model was not significant.
Table 3 displays the conditional multivariate models which include
the ERAP1 haplotypes in recessive models and the HLA-B risk
factors (HLA-B*51 or B*57 yes/no). The OR values among
individuals carrying the HLA-B risk factors were increased more
than 2 fold in both, the H2H2 and H3H3 individuals, whereas this
value remains the same for H1H1 subjects. Of note, individuals
bearing simultaneously H4H4 and the HLA-B risk factors were all
patients. In order to analyze the influence of the doses, individuals
were grouped in four different categories. Homozygous, subjects
with the same set of mutations in all their molecules (‘‘Ho’’, H2H2,
H3H3, H4H4); double heterozygous, individuals in which all the
molecules are mutated but each half has a different set of
mutations (‘‘dHe’’, H2H3, H2H4 and H3H4); heterozygous,
subject having half of molecules with and the other half without
mutations (‘‘He’’, H1H2, H1H3 and H1H4); and finally, normal
individuals, those having no molecules with these mutations (‘‘N’’,
H1H1). Next, conditional multivariate models taking into account
both, the condition HLA-B risk associated with BD (HLA-B*51 or
B*57 yes/no) and the ERAP1 mutation status (Ho, He, dHe and
N) were constructed. Table 4 displays the results of this analysis,
the OR values among individuals carrying the HLA-B risk factors
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Table 3. Conditional logistic regression models of HLA-B and of ERAP1 haplotypes.
HLA-B Risk H1H1 PatientsN = 343 Controls N = 450 P OR (95%CI)
+ + 28 13 ,1025 4.35 (2.19–8.64)
+ - 150 70 ,1025 4.33 (3.07–6.11)
- + 14 62 0.01 0.46 (0.25–0.84)
- - 151 305 1.0
HLA-B Risk H2H2
+ + 23 6 ,1025 8.54 (3.40–21.42)
+ - 155 77 ,1025 4.48 (3.20–6.28)
- + 20 44 .0.05
- - 145 323 1.0
HLA-B Risk H3H3
+ + 6 1 0.015 13.82 (1.65–115.72)
+ - 172 82 ,1025 4.83 (3.49–6.68)
- + 10 10 .0.05
- - 155 357 1.0
HLA-B Risk H4H4
+ + 3 0 .0.05
+ - 175 83 ,1025 4.73 (3.44–6.52)
- + 2 1 .0.05
- - 163 366 1.0
doi:10.1371/journal.pone.0102100.t003
Table 4. Conditional logistic regression models of HLA-B and three different conditions of ERAP1.
Factor B Ho Patients N = 343 Controls N = 450 P OR (95% CI)
+ + 32 7 ,1025 10.72 (4.62–24.91)
+ - 146 76 ,1025 4.51 (3.20–6.35)
- + 32 55 .0.05
- - 133 312 1.0
Factor B He
+ + 79 40 ,1025 5.03 (3.16–7.98)
+ - 99 43 ,1025 5.86 (3.75–5.14)
- + 88 171 .0.05
- - 77 196 1.0
Factor B dHe
+ + 39 23 ,1025 3.64 (2.09–6.34)
+ - 139 60 ,1025 4.98 (3.45–7.18)
- + 31 79 .0.05
- - 134 288 1.0
Factor B N
+ + 28 13 ,1025 4.35 (2.19–8.64)
+ - 150 70 ,1025 4.33 (3.07–6.11)
- + 14 62 0.01 0.46 (0.25–0.84)
- - 151 305 1.0
‘‘Ho’’ are individuals H2H2,H3H3 and H4H4; ‘‘He’’ are individuals H1H2,H1H3 and H1H4; ‘‘dHe’’ are individuals H2H3,H2H4 and H3H4; ‘‘N’’ are individuals H1H1.
CI confidence interval.
doi:10.1371/journal.pone.0102100.t004
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were increased from 4.51 to 10.72 in the ‘‘Ho’’ positive
individuals. Nevertheless, this effect was not observed in ‘‘He’’
nor in ‘‘dHe’’ subjects which have similar results as those obtained
in the group ‘‘N’’.
Discussion
Our results are consistent with the previously described
association of ERAP1 with BD in the Turkish population [12],
because the effects detected in our population have the same
direction as those described in the original paper, nevertheless,
associations and interactions were not statistically significant in the
Spanish population.
We decided to attempt the replication in our cohort of BD
patients because, additionally to the findings in GWAS, ERAP1 is
an interesting candidate in immune-mediated diseases associated
to HLA class I. In fact, the relationship of this gene with AS, which
like BD is associated with HLA class I molecules, seems well
established. Most of the studies investigating the influence of the
ERAP1 gene in susceptibility to AS include the rs27044 and
rs30187 and the authors report the minor alleles of these SNPs as
risk factors for this pathology in Caucasian [18,26–30] as well as in
Asian populations [31,32] and in meta-analysis studies [33,34].
Regarding the other 3 SNPs included in our study, rs17482078,
rs100504860 and rs2287987, their minor alleles have been
described as protective to AS in some studies but they have been
non-associated in others [18,26–28,31]. Notably, these last 3 SNPs
have MAFs lower than rs27044 and rs30187 in different
populations and the difference is particularly marked in Asian
populations (about 0.07 rs17482078, rs100504860 and rs2287987
vs. 0.50 for rs27044 and rs30187). The low frequency of these
SNPs determines a low statistical power, especially in some Asian
populations where BD is relatively common, which makes difficult
the replication of this finding. In fact, the association between the
rs17482078 and susceptibility to this disease which was described
in the Turkish population in the original report was not replicated
in the same study in the Japanese population. Additionally, the
strength of the association could be different among cohorts. Thus,
the OR values found in our cohort were lower than those detected
in the original study, causing a reduction in statistical power,
which a priori was higher than 99% for all the SNPs included.
Nevertheless, our results were not discrepant with the original
report because according to the recessive model found by Kirino
et al [12], the frequencies of the homozygous for the minor alleles
were higher among patients for all the SNPs and according to an
epistatic interaction with the HLA, the OR values were higher
among patients with the HLA-B risk factors, although the
differences were not significant.
The rs27044 and the rs30187 are in LD with each other
(r2 = 0.75, D9= 0.97) and the rs17482078, the rs100504860 and
the rs2287987 are also in LD with each other (r2 and D9 values
greater than 0.90 in the European population). In spite of this
strong LD most of the studies in AS include these 5 non-
synonimous ERAP1 polymorphisms. Four major haplotypes
(named from H1 to H4 in Table 2) are obtained by the
combination of the variations of these five SNPs according to
data from CEU and also from our population. The H2 and H3
correspond respectively with risk and protection haplotypes in AS
[34,35], however, our data suggest that both haplotypes could be
risk factors in BD. Association of ERAP1 with AS is restricted to
individuals bearing the HLA-B risk factor for this disease, HLA-
B27, [35,36] whereas in psoriasis the relationship between ERAP1
and HLA-C remains unclear [19,37]. Althought our results
require further confirmation, data displayed in Tables 3 and 4
support a model in which the presence of the same mutation in
both chromosomes increased the susceptibility risk in individuals
bearing the HLA-B risk factors. ERAP1 is located in the ER
where it is one of the enzymes trimming peptides to reach the
optimal size for class I MHC binding. A reduction of the trimming
activity for the protective alleles for AS has been found in studies
investigating individual changes associated with AS [38–40]. Very
recently, the influence of the natural haplotypes of ERAP1 in
trimming activity has been explored [41]. These authors suggested
that there is a range of trimming activity among the ERAP1 alleles
with some of them encoding molecules that overtrim and others
that undertrim. Both conditions, over and under activity could be
associated with diseases. The ‘‘Ho’’ status is a scenario in which all
the ERAP1 molecules of one individual have the same mutations,
producing a lower number of peptides with the appropriate size.
Nevertheless, the ‘‘dHe’’ individuals have two different ERAP1
molecules. If one of them over trims whereas the other under
trims, the compensation of the enzimatic activity could generate a
larger number of units with the appropriate size.
In conclusion, data in the Spanish population were consistent
with association between ERAP1 and BD as well as with an
epistatic interaction between ERAP1 and HLA-B described in the
Turkish population, although our results were not statistically
significant.
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